Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia

CNS Spectrums

Volumn 13, Issue 3 SUPPL. 5, 2008, Pages 12-17

  Staud, Roland ^a,c   Spaeth, Michael ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Center for Clinical Rheumatology Research   (Germany)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; CORTICOTROPIN RELEASING FACTOR; EXCITATORY AMINO ACID; EXCITATORY AMINO ACID RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; MUSCLE RELAXANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NARCOTIC ANALGESIC AGENT; NERVE GROWTH FACTOR; NEUROKININ 1 RECEPTOR; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST;

AFFECT; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHRONIC PAIN; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; FATIGUE; FIBROMYALGIA; GLIA CELL; HELP SEEKING BEHAVIOR; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IRRITABLE COLON; LOW BACK PAIN; MAJOR DEPRESSION; MIGRAINE; MYOFASCIAL PAIN; NERVE CELL PLASTICITY; NERVE FIBER C; NEUROCHEMISTRY; NOCICEPTIVE STIMULATION; PAIN; PAIN THRESHOLD; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOPHYSICS; REVIEW; SENSITIZATION; SENSORY NERVE; SLEEP; TEMPORAL SUMMATION;

EID: 42149191226     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s109285290002678x     Document Type: Review

References (65)

1. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37(11):1593-1601.
2. Bradley LA, Alarcon GS, Sotolongo A, et al. Cerebrospinal fluid (CSF) levels of substance P (SP) are abnormal in patients with fibromyalgia (FM) regardless of traumatic or insidious pain onset. Arthritis Rheum. 1998;41:256.
3. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988;32(1):21-26.
4. Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol Suppl. 2000;113:8-12.
5. Lautenschlager J, Bruckle W, Schnorrenberger CC, Muller W. [Measuring pressure pain of tendons and muscles in healthy probands and patients with generalized tendomyopathy (fibromyalgia syndrome)]. Z Rheumatol. 1988;47(6):397-404.
6. Quimby LG, Block SR, Gratwick GM. Fibromyalgia: generalized pain intolerance and manifold symptom reporting. J Rheumatol. 1988;15(8):1264-1270.
7. Tunks E, Crook J, Norman G, Kalaher S. Tender points in fibromyalgia. Pain. 1988;34(1):11-19.
8. Mikkelsson M, Latikka P, Kautiainen H, Isomeri R, Isomaki H. Muscle and bone pressure pain threshold and pain tolerance in fibromyalgia patients and controls. Arch Phys Med Rehabil. 1992;73(9):814-818.
9. Kosek E, Ekholm J, Hansson P. Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain. 1995;63(3):335-339.
10. Crofford LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004;18(4):314-325.
11. Crofford LJ. The hypothalamic-pituitary-adrenal axis in fibromyalgia: Where are we in 2001? J Musculoskelet Pain. 2002;10:215-220.
12. Bradley LA, Sotolongo A, Alberts KR, et al. Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J Musculoskelet Pain. 1999;7:285-292.
13. Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain. 2000;87(2):201-211.
14. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999;26(7):1564-1569.
15. Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. J Musculoskelet Pain. 1995;3(suppl):4.
16. Bradley LA, Alberts KR, Alarcon GS, et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis Rheum. 1996;39(suppl 19):212.
17. Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci. 1998;315(6):377-384.
18. Almay BG, Johansson F, Von-Knorring L, Le-Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain. 1988;33(1):3-9.
19. Fischer HP, Eich W, Russell IJ. A possible role for saliva as a diagnostic fluid in patients with chronic pain. Semin Arthritis Rheum. 1998;27(6):348-359.
20. Sjostrom S, Tamsen A, Hartvig P, Folkesson R, Terenius L. Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg. 1988;67(10):976-981.
21. Murphy RM, Zemlan FP. Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacol (Berl). 1987;93(1):118-121.
22. Schwarz MJ, Späth M, Müller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett. 1999;259(3):196-198.
23. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia J Rheumatol. 1999;26(7):1564-1569.
24. Crofford LJ, Engleberg NC, Demitrack MA. Neurohormonal perturbations in fibromyalgia. Baillieres Clin Rheumatol. 1996;10(2):365-378.
25. Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic-pituitary- adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37(11):1583-1592.
26. Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am. 2000;26(4):989-1002.
27. Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25(1):1-35.
28. Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR. Responses of the sympathetic nervous system and the hypothalamic-pituitary- adrenal axis to interleukin-6: A pilot study in fibromyalgia. Arthritis Rheum. 2000;43(4):872-880.
29. McLean SA, Williams DA, Stein PK, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology. 2006;31(12):2776-2782.
30. Fuller RW. The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol. 1992;13(3):250-270.
31. Fuller RW. Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Behav Brain Res. 1996;73(1-2):215-219.
32. Simms RW. Fibromyalgia is not a muscle disorder. Am J Med Sci. 1998;315:346-350.
33. Sprott H, Bradley LA, Oh SJ, et al. Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum. 1998;41(9):1689-1694.
34. Sprott H, Salemi S, Gay RE et al. Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres. Ann Rheum Dis. 2004;63(3):245-251.
35. Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol. 2003;30(1):146-150.
36. Mclver KL, Evans C, Kraus RM, Ispas L, Sciotti VM, Hickner RC. NO-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain. 2006;120(1-2):161-169.
37. Graven-Nielsen T, Arendt-Nielsen L. Is there a relation between intramuscular hypoperfusion and chronic muscle pain? J Pain. 2002;3(4):261-263.
38. Elvin A, Siosteen AK, Nilsson A, Kosek E. Decreased muscle blood flow in fibromyalgia patients during standardised muscle exercise: A contrast media enhanced colour Doppler study. Eur J Pain. 2006;10(2):137-144.
39. Staud R, Vierck CJ, Robinson ME, Price DD. Overall fibromyalgia pain is predicted by ratings of local pain and pain related negative affect: possible role of peripheral tissues. Rheumatology (Oxford). 2006;45(11):1409-1415.
40. Forseth KO, Forre O, Gran JT. A 5.5 year prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population: significance and natural history. Clin Rheumatol. 1999;18(2):114-121
41. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum. 2001;44(4):940-946.
42. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944-952.
43. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med. 2004;66(6):837-844.
44. Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain. 2004;110(1-2):449-460.
45. Woolf CJ. Windup and central sensitization are not eguivalent. Pain. 1996;66(2-3):105-108.
46. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain. 1999;79(1):75-82.
47. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46(5):1333-1343.
48. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91(1-2):165-175.
49. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the freguency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology. 1987;26:1235-1238.
50. Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci USA. 1999;96(14):7723-7730.
51. Staud R, Domingo M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med. 2001;2(3):208-215.
52. Staud R, Domingo M. New Insights into the pathogenesis of fibromyalgia syndrome. Med Aspects Hum Sex. 2001;1:51-57.
53. Vierck CJ, Staud R, Price DD, et al. The effect of maximal exercise on temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. J Pain. 2001;2(6):334-344.
54. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002;4(4):299-305.
55. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99(1-2):49-59.
56. Staud R, Robinson ME, Vierck CJ Jr, Cannon RC, Mauderli AP, Price DD. Ratings of experimental pain and pain-related negative affect predict clinical pain in patients with fibromyalgia syndrome. Pain. 2003;105(1-2):215-222.
57. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24(8):450-455.
58. Wieseler-Frank J, Maier SF. Watkins LR. Glial activation and pathological pain. Neurochem Int. 2004;45:389-395.
59. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005;14(4):166-174.
60. Watkins LR, Maier SF. When good pain turns bad. Curr Dir Psychol Sci. 2003;12(6):232-236.
61. Salter MW. Cellular signalling pathways of spinal pain neuroplasticity as targets for analgesic development. Curr Top Med Chem. 2005;5:557-567.
62. Cook AJ, Woolf CJ, Wall PD, McMahon SB. Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input. Nature. 1987;325(7000):151-153.
63. Vierck CJ, Jr. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain. 2006;124(3):242-263.
64. Bazzichi L, Giannaccini G, Betti L et al. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther. 2006;8(4):R99.
65. Delgado PL. Serotonin noradrenaline reuptake inhibitors: New hope for the treatment of chronic pain. Int J Psychiatr Clin Pract. 2006;10:16-21.